1
Clinical Trials associated with HIV 1 antigen expanded specific T cell(University of North Carolina)IGHID 11627 - A Phase I Study to Evaluate the Effects of Vorinostat and HIV-1 Antigen Expanded Specific T Cell Therapy (HXTC) on Persistent HIV-1 Infection in HIV-Infected Individuals Started on Antiretroviral Therapy (The XTRA Study)
This is a phase I, single-site, study to evaluate the effects of VOR and HIV-1 Antigen Expanded Specific T Cell Therapy (HXTC) on persistent HIV-1 Infection in HIV-infected individuals suppressed on ART. Twelve participants with durable viral suppression will be enrolled and will complete the study. All participants will receive the same treatment and if eligible, will be dosed with HXTC and VOR. Participants will continue their baseline ART regimen throughout the study.
100 Clinical Results associated with HIV 1 antigen expanded specific T cell(University of North Carolina)
100 Translational Medicine associated with HIV 1 antigen expanded specific T cell(University of North Carolina)
100 Patents (Medical) associated with HIV 1 antigen expanded specific T cell(University of North Carolina)
100 Deals associated with HIV 1 antigen expanded specific T cell(University of North Carolina)